Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~≥ 18 years of age~Potassium ≥5.8 mmol/L~Exclusion Criteria:~Possible pseudohyperkalaemia~Hyperkalaemia caused by any condition for which a therapy directed against the underlying cause of hyperkalaemia would be a better treatment option than treatment with insulin and glucose.~Dialysis session expected within 4h after randomization~Treated with any therapy intended to lower S-K between arriving at the hospital and randomization during Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- ZS+insulin+glucose (Type: EXPERIMENTAL): ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
- Placebo+insulin+glucose (Type: PLACEBO_COMPARATOR): Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).